Pharmacology & ToxicologybioRxiv
Combined in silico docking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43 inhibitors
M. Milani, M. Donalisio, R. M. Bonotto…·E. Mastrangelo
The paper identifies lurasidone and elbasidone as inhibitors of SARS-CoV-2 and HCoV-OC43 through in silico docking and in vitro testing.
DOI 10.1016/j.antiviral.2021.105055